Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
BAF complex
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "BAF complex" in MCE Product Catalog:
4
4 Cited Publications
BRD-K98645985 is a BAF (mammalian SWI/SNF) transcriptional repression inhibitor with an EC50 of ~2.37 μM. BRD-K98645985 binds ARID1A-specific BAF complexes, prevents nucleosomal positioning, and potently reverses HIV-1 latency, without T cell activation or toxicity .
3
3 Cited Publications
Target:
Domaines de recherche:
PROTAC BRD9 Degrader-1 is a PROTAC connected by ligands for Cereblon and BRD9 (IC50=13.5 nM), which can be used as a selective probe useful for the study of BAF complex biology .
Cat. No.: HY-148374
CAS No.: 2422030-94-0
Target:
Domaines de recherche:
BRM/BRG1 ATP Inhibitor-4 is a BRG1/BRM inhibitor. BRM/BRG1 ATP Inhibitor-4 can be used for the research of cancers and BAF complex-related disorders .
Domaines de recherche:
Thalidomide-NH-PEG2-C2-NH-Boc is a synthesized?E3 ligase ligand-linker conjugate?that incorporates the?Thalidomide?based cereblon ligand and a PEG linker used for dBRD9 (compound 6) synthesis. dBRD9 is a selective BRD9 probe PROTAC degrader for the study of BAF complex biology .
Target:
Domaines de recherche:
PROTAC BRD9 Degrader-6 (Compound D1) is a racemic PROTAC degrader that recruits cereblon to induce targeted degradation of BRD9. PROTAC BRD9 Degrader-6 has an IC50 of 0.13 nM in SYO-1 cells. It can be used in research on BAF complex-related diseases, such as cancer, infections and synovial sarcoma .
Cat. No.: HY-178481
CAS No.: 2468046-57-1
Target:
Domaines de recherche:
BRM/BRG1 ATP-IN-5 (Compound 6) is a BRG1/BRM inhibitor. BRM/BRG1 ATP-IN-5 acts on the BAF complex, which is involved in chromatin regulation and gene expression via ATP-dependent chromatin remodeling. BRM/BRG1 ATP-IN-5 demonstrates anti-tumor potential, particularly in cancers associated with BAF complex disorders .
Cat. No.: HY-178484
CAS No.: 2468049-60-5
Target:
Domaines de recherche:
BRM/BRG1 ATP-IN-6 (Compound 105) is a BRG1/BRM inhibitor. BRM/BRG1 ATP-IN-6 acts on the BAF complex, which is involved in chromatin regulation and gene expression via ATP-dependent chromatin remodeling. BRM/BRG1 ATP-IN-6 demonstrates anti-tumor potential, particularly in cancers associated with BAF complex disorders .
Cat. No.: HY-148373
CAS No.: 2368901-31-7
Target:
Domaines de recherche:
BRM/BRG1 ATP Inhibitor-3 is a BRG1/BRM inhibitor. BRM/BRG1 ATP Inhibitor-3 inhibits BRM and BRG1 with IC50 values of 10.4 nM and 19.3 nM, respectively. BRM/BRG1 ATP Inhibitor-3 can be used for the research of cancers and BAF complex-related disorders .
Cat. No.: HY-P86786
Synonyms: BAF 170 antibody; BAF170 antibody; BRG1 associated factor 170 antibody; BRG1-associated factor 170 antibody; Chromatin remodeling complex BAF170 subunit antibody; CRACC 2 antibody; CRACC2 antibody; Mammalian chromatin remodeling complex BRG1 associated factor 170 antibody; Rsc 8 antibody; Rsc8 antibody; BAF 170 antibody; BAF170 antibody; BRG1 associated factor 170 antibody; BRG1-associated factor 170 antibody; Chromatin remodeling complex BAF170 subunit antibody; CRACC 2 antibody; CRACC2 antibody; Mammalian chromatin remodeling complex BRG1 associated factor 170 antibody; Rsc 8 antibody; Rsc8 antibody; SMARCC 2 antibody; Smarcc2 antibody; SMRC2_HUMAN antibody; SWI/SNF complex 170 kDa subunit antibody; SWI/SNF complex subunit SMARCC2 antibody; SWI/SNF related matrix associated actin dependent regulator of chromatin c2 antibody; SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily c member 2 antibody; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily C member 2 antibody; SWI3 like protein antibody;
Cat. No.: HY-180886
Target:
Domaines de recherche:
ZD-1-186 is a nondegradative molecular glue that potently suppresses MYC and robustly induces CDKN1A (p21) in diffuse large B-cell lymphoma cells. ZD-1-186 brings together BCL6 with BRD9, a noncanonical BAF complex bromodomain protein implicated in maintaining MYC transcriptional output in specific lymphoma contexts. ZD-1-186 can be used for targeted transcriptional rewiring research .
Cat. No.: HY-P85564
Synonyms: AI115498; BAF 155; BAF155; BRG 1 associated factor 155; BRG1 associated factor 155; BRG1-associated factor 155; Chromatin remodeling complex BAF155 subunit; CRACC 1; CRACC1; Mammalian chromatin remodeling complex BRG 1 associated factor 155; Mammalian chromatin remodeling complex BRG1 associated factor 155; Rsc 8; Rsc8; SMARC C1; SMARCC 1; SMARCC1; SMRC1_HUMAN; SRG 3; SRG3; SWI 3; SWI/SNF complex 155 kDa subunit; SWI/SNF related matrix associated actin dependent regulator of chromatin c1; SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily c member 1; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily C member 1; SWI3.
Cat. No.: HY-P87888
Synonyms: BAF250, BAF250A, C1orf4, OSA1, SMARCF1, ARID1A, AT-rich interactive domain-containing protein 1A, ARID domain-containing protein 1A, B120, BRG1-associated factor 250, BRG1-associated factor 250a, Osa homolog 1, SWI-like protein, SWI/SNF complex protein p270, hELD, hOSA1
Cat. No.: HY-185075
CAS No.: 3008577-34-9
Synonyms: LY4050784
Target:
Domaines de recherche:
FHD-909 (LY4050784) is an orally active and selective SMARCA2 (BRM) ATPase inhibitor. FHD-909 potently inhibits purified BRM ATPase with an IC50 of 0.0025 μM and exhibits 35.69-fold selectivity for BRM over purified SMARCA4 (BRG1) ATPase. FHD-909 induces synthetic lethality, suppresses cell proliferation, modulates target gene expression, and achieves remarkable tumor growth inhibition and regression in SMARCA4-mutant cancer cells and xenograft models. FHD-909 can be used for the research of SMARCA4/BRG1-mutant cancers, advanced solid tumors, and BAF complex-related disorders .
Cat. No.: HY-P85957
Synonyms: BAF47; BRG1-associated factor 47; hSNF5; INI1; Integrase interactor 1 protein; Malignant rhabdoid tumor suppressor; RDT; RTPS1; Sfh1p; SMARCB1; SNF5 homolog; SNF5_HUMAN; SNF5L1; Snr1; Sucrose nonfermenting yeast homolog like 1; SWI/SNF complex component SNF5; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1; SWI10; Transcription factor TYE4; Transcription regulatory protein SNF5; TYE4
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
